Trastuzumab (Herceptin®) is a monoclonal antibody that interferes with the growth factor receptor HER2 (which is overexpressed in about 20% of breast cancer patients) and its use have changed the natural history of the HER2-positive breast cancer by improving the disease-free and overall survival [8]. Here, ERBB2 is linked to breast carcinoma.